The first report implicating acquired RyR2 dysfunction in heart failure was published in 2000 [5], whereas a year later came the first studies associating mutations in the RYR2 gene with catecholaminergic polymorphic ventricular tachycardia (CPVT) and arrhythmogenic right ventricular dysplasia type 2 (ARVD2) [6,7,8]. This evidence concerns the gene RYR2 and catecholaminergic polymorphic ventricular tachycardia.